FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023650657> ?p ?o ?g. }

• W2023650657 endingPage "1238" @default.
• W2023650657 startingPage "1229" @default.
• W2023650657 abstract "The results of several clinical trials using various luteinizing hormone-releasing hormone agonists for treatment of advanced breast cancer are encouraging. However, only about 30% of breast cancers are estrogen-dependent and can be treated by hormonal manipulation. New therapeutic approaches combining estrogen ablation therapy with other compounds must be explored. Various studies suggest that bombesin or gastrin-releasing peptide acts as an autocrine growth factor and may play a role in the initiation and progression of some cancers, including that of the breast.Female athymic nude mice bearing xenografts of the MCF-7 MIII human breast cancer cell line were treated for 7 weeks with bombesin/gastrin-releasing peptide antagonist (D-Tpi6, Leu13 psi[CH2NH]-Leu14) bombesin(6-14) (RC-3095) injected subcutaneously daily at a dose of 20 micrograms and luteinizing hormone-releasing hormone antagonist SB-75 (Cetrorelix) administered biweekly in the form of microgranules releasing 45 micrograms/day.After 2 weeks of treatment, a significant inhibition of tumor volume was observed in the groups treated with RC-3095 alone or in combination with SB-75 but not in those treated with SB-75 as a single agent. After 7 weeks, tumor growth as measured by tumor volume and percentage changes in tumor volume and tumor weight was greatly inhibited in all of the treated groups. Uterine and ovarian weights were reduced and serum luteinizing hormone levels decreased by administration of SB-75 alone or in combination with RC-3095. Histologically, a significant decrease in argyrophilic nucleolar organizer region count in tumor cell nuclei was observed in all of the treated groups, indicating a lower proliferation of these cells. High-affinity binding sites for bombesin were detected in cultured MCF-7 MIII cells. Chronic treatment with RC-3095 caused a significant down-regulation of epidermal growth factor receptors in tumor cell membranes, which might be related to tumor inhibition. In studies in vitro, SB-75 inhibited proliferation of MCF-7 cells in culture but not proliferation of MCF-7 MIII cells.Because previously we demonstrated that RC-3095 inhibits the proliferation of MCF-7 MIII cells in vitro, it appears that the major antitumoral effect of RC-3095 on the MCF-7 MIII cancer line is direct, whereas that of SB-75 is indirect, and that it is mediated by suppression of the pituitary-gonadal axis. In view of its immediate and powerful inhibitory effect on MCF-7 MIII tumors, bombesin/gastrin-releasing peptide antagonist RC-3095 might be considered as a possible new agent for the treatment of breast cancer." @default.
• W2023650657 created "2016-06-24" @default.
• W2023650657 creator A5008707617 @default.
• W2023650657 creator A5013036085 @default.
• W2023650657 creator A5029989187 @default.
• W2023650657 creator A5047212274 @default.
• W2023650657 creator A5065215059 @default.
• W2023650657 creator A5068739269 @default.
• W2023650657 creator A5072430373 @default.
• W2023650657 date "1994-02-15" @default.
• W2023650657 modified "2023-10-18" @default.
• W2023650657 title "Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone—releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice" @default.
• W2023650657 cites W1972020194 @default.
• W2023650657 cites W1974048152 @default.
• W2023650657 cites W1974393133 @default.
• W2023650657 cites W1975338624 @default.
• W2023650657 cites W1982186695 @default.
• W2023650657 cites W1991915284 @default.
• W2023650657 cites W1994843266 @default.
• W2023650657 cites W1996324157 @default.
• W2023650657 cites W1997479018 @default.
• W2023650657 cites W2003161894 @default.
• W2023650657 cites W2004995620 @default.
• W2023650657 cites W2007329410 @default.
• W2023650657 cites W2009981615 @default.
• W2023650657 cites W2011695495 @default.
• W2023650657 cites W2011889777 @default.
• W2023650657 cites W2019042050 @default.
• W2023650657 cites W2019811067 @default.
• W2023650657 cites W2030847748 @default.
• W2023650657 cites W2031956553 @default.
• W2023650657 cites W2032346433 @default.
• W2023650657 cites W2033312402 @default.
• W2023650657 cites W2038243639 @default.
• W2023650657 cites W2043813981 @default.
• W2023650657 cites W2047607406 @default.
• W2023650657 cites W2052628486 @default.
• W2023650657 cites W2068759946 @default.
• W2023650657 cites W2070971135 @default.
• W2023650657 cites W2077343800 @default.
• W2023650657 cites W2082484682 @default.
• W2023650657 cites W2086197710 @default.
• W2023650657 cites W2095946391 @default.
• W2023650657 cites W2101679711 @default.
• W2023650657 cites W2114712559 @default.
• W2023650657 cites W2126943550 @default.
• W2023650657 cites W2149308203 @default.
• W2023650657 cites W2155127143 @default.
• W2023650657 cites W4159394 @default.
• W2023650657 doi "https://doi.org/10.1002/1097-0142(19940215)73:4<1229::aid-cncr2820730417>3.0.co;2-1" @default.
• W2023650657 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8313327" @default.
• W2023650657 hasPublicationYear "1994" @default.
• W2023650657 type Work @default.
• W2023650657 sameAs 2023650657 @default.
• W2023650657 citedByCount "46" @default.
• W2023650657 countsByYear W20236506572012 @default.
• W2023650657 countsByYear W20236506572014 @default.
• W2023650657 countsByYear W20236506572015 @default.
• W2023650657 countsByYear W20236506572016 @default.
• W2023650657 countsByYear W20236506572018 @default.
• W2023650657 countsByYear W20236506572019 @default.
• W2023650657 countsByYear W20236506572021 @default.
• W2023650657 countsByYear W20236506572022 @default.
• W2023650657 crossrefType "journal-article" @default.
• W2023650657 hasAuthorship W2023650657A5008707617 @default.
• W2023650657 hasAuthorship W2023650657A5013036085 @default.
• W2023650657 hasAuthorship W2023650657A5029989187 @default.
• W2023650657 hasAuthorship W2023650657A5047212274 @default.
• W2023650657 hasAuthorship W2023650657A5065215059 @default.
• W2023650657 hasAuthorship W2023650657A5068739269 @default.
• W2023650657 hasAuthorship W2023650657A5072430373 @default.
• W2023650657 hasBestOaLocation W20236506571 @default.
• W2023650657 hasConcept C109541995 @default.
• W2023650657 hasConcept C118303440 @default.
• W2023650657 hasConcept C121608353 @default.
• W2023650657 hasConcept C126322002 @default.
• W2023650657 hasConcept C134018914 @default.
• W2023650657 hasConcept C170493617 @default.
• W2023650657 hasConcept C2776885963 @default.
• W2023650657 hasConcept C2776998989 @default.
• W2023650657 hasConcept C2777164284 @default.
• W2023650657 hasConcept C2778448772 @default.
• W2023650657 hasConcept C2778575703 @default.
• W2023650657 hasConcept C2994423619 @default.
• W2023650657 hasConcept C530470458 @default.
• W2023650657 hasConcept C71315377 @default.
• W2023650657 hasConcept C71924100 @default.
• W2023650657 hasConceptScore W2023650657C109541995 @default.
• W2023650657 hasConceptScore W2023650657C118303440 @default.
• W2023650657 hasConceptScore W2023650657C121608353 @default.
• W2023650657 hasConceptScore W2023650657C126322002 @default.
• W2023650657 hasConceptScore W2023650657C134018914 @default.
• W2023650657 hasConceptScore W2023650657C170493617 @default.
• W2023650657 hasConceptScore W2023650657C2776885963 @default.
• W2023650657 hasConceptScore W2023650657C2776998989 @default.
• W2023650657 hasConceptScore W2023650657C2777164284 @default.
• W2023650657 hasConceptScore W2023650657C2778448772 @default.
• W2023650657 hasConceptScore W2023650657C2778575703 @default.

• next